Immunome (NasdaqCM:IMNM) FY Conference Transcript

Summary of Immunome FY Conference Call - December 03, 2025 Company Overview - Company: Immunome (NasdaqCM:IMNM) - Focus: Targeted therapies for cancer, primarily through antibody-drug conjugates (ADCs), radioligands, and targeted small molecules like variegated statin [2][3] Key Points on Pipeline and Products Variegated Statin and AL102 - AL102: A small molecule inhibitor of gamma secretase in a Phase 3 study called RINGSIDE, targeting desmoid tumors, a type of cancer with no previously approved therapies [4] - Objective: To provide a better treatment option with a higher response rate and deeper tumor regression compared to existing therapies [5] - Phase 3 Trial: Expected to unblind data soon, with primary endpoint being progression-free survival (PFS) [6] - Comparison with Nirogacestat: Previous study showed 41% objective response rate (ORR) and 59% median tumor reduction; Immunome aims to exceed these results [8][9] Safety Profile - Safety Monitoring: No significant safety issues reported by the data safety monitoring board during the Phase 3 trial [13][14] - Side Effects: Expected side effects, but no major differentiations from Nirogacestat's profile noted in Phase II [14][15] Commercialization Plans - Regulatory Submission: Plans to submit for regulatory approval within four to five months post-data unblinding [17][18] - Global Launch Strategy: Plans to launch in the US, Canada, Europe, and use distributors in Latin America and the Middle East [19][20] ADC Pipeline IM1021 and ROR1 Targeting - ROR1 ADC: In early clinical development, targeting B-cell lymphoma; objective responses observed in Phase I trials [21][27] - ADC Technology: Development of ADC 3.0, addressing issues of resistance and deconjugation seen in previous ADC technologies [24][25] - Differentiation from Competitors: Aiming for higher response rates (50-70%) compared to Merck's ROR1 ADC, which has shown lower response rates [33][34] Future Development - IND Plans: Three INDs planned for 2026 and three for 2027, focusing on large solid tumor markets [27][28] Additional Insights - Patient Considerations: Emphasis on the need for rapid response in treatments for painful conditions like desmoid tumors [11][12] - Market Positioning: Aiming to differentiate products in a crowded market by demonstrating superior efficacy and safety profiles [34][35] This summary encapsulates the key points discussed during the Immunome FY Conference Call, highlighting the company's focus on innovative cancer therapies and strategic plans for product development and commercialization.